Listen on the go
CORRECT!
Next question
touchDERMATOLOGY touchDERMATOLOGY

Start Learning

Touch Loading image
touchPANEL DISCUSSION
Start Learning
Multidisciplinary insights: Navigating the challenges of systemic mastocytosis diagnosis and management
CE/CME ACCREDITED
CONFERENCE HUB
Start Learning
Victoria P. Werth: The phase 3 DeterMine trial of lenabasum in dermatomyositis Recent content from our partner site touchIMMUNOLOGY
CONFERENCE HUB
Start Learning
A-STAR register, comparing dupilumab and methotrexate in atopic dermatitis: Carsten Flohr
CONFERENCE HUB
Start Learning
Changing the Treatment Paradigm in Generalized Pustular Psoriasis | Insights from AAD 2023
CONFERENCE HUB
Start Learning
Melinda Gooderham, Dermatology Meeting News 2023: Abrocitinib efficacy in atopic dermatitis by baseline disease severity – findings from an interim analysis of JADE EXTEND
Recent content from our partner site touchIMMUNOLOGY
CONFERENCE HUB
Start Learning
Thierry Passeron: Efficacy of Ruxolitinib Cream by Body Region in Vitiligo – A Pooled Analysis of the TRuE-V Phase 3 StudiesRecent content from our partner site touchIMMUNOLOGY
CONFERENCE HUB
Start Learning
Remibrutinib in chronic spontaneous urticaria patients: phase 3b extension trial: Marcus Maurer, EAACI 2023
Recent content from our partner site touchIMMUNOLOGY
touchMDT
Start Learning
Establishing treatment and care pathways for patients with prurigo nodularis: A patient-centric focus from multidisciplinary perspectives
CE/CME ACCREDITED
expert highlights from EADV 2023
CONFERENCE HUB
Start Learning
Key insights: Pigmentary disorders, atopic dermatitis, aesthetic medicine and autoimmune diseases, EADV 2023
journal placeholder
JOURNALS
Start Learning
New study links rosacea with increased risk of malignant melanoma

to view Favourites, Keep Notes and Track CME Credits

Favourites
2024 AAD ANNUAL MEETING American Academy of Dermatology
View
The Role of Ixekizumab in Palmoplantar Psoriasis | Insights from AAD 2023
View
Vaccination and the antibiotic landscape of cutaneous sexually transmitted infections: Georg Stary
View
Raj Chovatiya, Dermatology Meeting News 2023: Efficacy & safety profile of baricitinib for inflammatory dermatologic disease
Recent content from our partner site touchIMMUNOLOGY
View
Unlocking the pathogenesis of chronic spontaneous urticaria to inform the future treatment landscape
View
Amit G. Pandya, Dermatology Meeting News 2023: Efficacy & safety of ruxolitinib cream in vitiligo – findings from the TRuE-V phase 3 studies
Recent content from our partner site touchIMMUNOLOGY
View
What to Know About the Addition of Janus Kinase Inhibitors to the Dermatologist’s Armamentarium
View
William Damsky, Dermatology Meeting News 2023: A personalised approach to treating inflammatory skin diseases
Recent content from our partner site touchIMMUNOLOGY
View
OLYMPIA 2: nemolizumab improves prurigo nodularis-associated pain and patient reported outcomes: Adam Reich
View
Upadacitinib in a phase 2 study of adults with non-segmental vitiligo: Thierry Passeron
View
Copied to clipboard!
accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72